|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017.
|
30759187 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of Ultra and Xpert were compared to culture on respiratory specimens from patients with suspected pulmonary TB (November 2016 to August 2018; <i>n</i> = 196) in Lausanne (Switzerland).
|
30541937 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
IP-10 levels in plasma, DPS and DBS samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, were quantified by an enzyme-linked immunosorbent assay.
|
30846768 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Totally 689 cases were included.The direct head-to-head diagnostic performance comparison showed higher sensitivity of Xpert Ultra in contrast with Xpert among 292 smear-negative pulmonary TB (PTB) (70.89% vs 57.88%, P = 0.001), 108 tuberculous pleurisy (61.11% vs 34.26%, P<0.001), and 43 tuberculous meningitis (44.19% vs 18.60%, P = 0.011).
|
30796951 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert Ultra was found to have a higher sensitivity, but slightly reduced specificity compared to Xpert in detecting pulmonary tuberculosis in children.
|
30036606 |
2018 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical impact and costs incurred in adopting the Xpert test in routine PTB diagnosis was evaluated in a prospective study conducted from November 2012 to November of 2013, in the City of Rio de Janeiro, Brazil.
|
30304269 |
2018 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
GeneXpert MTB/RIF (Xpert) assay has been endorsed for the diagnosis of pulmonary TB due to its high sensitivity and specificity for culture positive TB.
|
29805972 |
2018 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity of the Xpert assay for detection of M. tuberculosis in stool samples of PTB patients was 90.2% (95% CI, 82.9-95.0).
|
30212505 |
2018 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a Markov microsimulation model of hypothetical cohorts of 100,000 individuals undergoing diagnostic sputum evaluation with Xpert for suspected pulmonary TB, in each of 3 emblematic settings: an HIV clinic in South Africa, a public TB center in India, and an adult primary care setting in China.
|
29240766 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we recommend MPCR alongside GeneXpert for the better diagnostic accuracy of PTB in a resource-limited country where tuberculosis is endemic.
|
28612135 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, Xpert MTB/RIF assay is being used for rapid diagnosis of pulmonary TB, but it has not yet been widely validated in intrathoracic TB lymphadenitis.
|
28372894 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert MTB/RIF (Cepheid) is a rapid molecular assay shown to be sensitive and specific for pulmonary tuberculosis (TB) diagnosis in highly endemic countries.
|
28237624 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stool Xpert<sup>®</sup> MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis at primary clinics in Zimbabwe.
|
28234079 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
|
28172666 |
2017 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia.
|
26724771 |
2016 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of GeneXpert MTB/RIF assay for direct diagnosis of pulmonary tuberculosis.
|
27652357 |
2016 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systematic review: Comparison of Xpert MTB/RIF, LAMP and SAT methods for the diagnosis of pulmonary tuberculosis.
|
26786658 |
2016 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The feasibility of using MTB/RIF and culture on stool and string test specimens from 13 adult patients with presumed PTB was studied.
|
26523638 |
2015 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluating the Diagnostic Accuracy of Xpert MTB/RIF Assay in Pulmonary Tuberculosis.
|
26496123 |
2015 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a prospective, cross-sectional study with 2-month follow-up comparing Xpert with standard strategies for evaluating outpatients for active pulmonary TB at the San Francisco Department of Public Health TB Clinic between May 2010 and June 2011.
|
24869625 |
2014 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of the Xpert(®) MTB/RIF molecular test on the late diagnosis of pulmonary tuberculosis.
|
24670698 |
2014 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that routine Xpert MTB/RIF testing is a promising solution to present-day challenges in the diagnosis of PTB in pediatric patients.
|
25140877 |
2014 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high proportion of very low mycobacterial load in the GLA samples from smear-negative TB cases may increase the frequency for obtaining indeterminate RIF resistance results by Xpert.
|
25361186 |
2014 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
|
24448973 |
2014 |
|
Tuberculosis, Pulmonary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sputum remains the optimal sample type for diagnosing pulmonary tuberculosis in HIV-negative patients with the Xpert assay.
|
24108610 |
2013 |